Cantor Fitzgerald set a $110.00 price objective on Global Blood Therapeutics (NASDAQ:GBT) in a research report released on Friday morning, Stock Target Advisor reports. The brokerage currently has a buy rating on the stock.

Several other analysts have also weighed in on the company. BidaskClub upgraded Global Blood Therapeutics from a hold rating to a buy rating in a report on Friday, May 10th. Wedbush restated an outperform rating and set a $95.00 price target on shares of Global Blood Therapeutics in a report on Thursday, April 18th. Goldman Sachs Group restated a neutral rating and set a $75.00 price target on shares of Global Blood Therapeutics in a report on Wednesday, May 29th. ValuEngine upgraded Global Blood Therapeutics from a buy rating to a strong-buy rating in a report on Monday, April 1st. Finally, Wells Fargo & Co increased their price target on Global Blood Therapeutics from $85.00 to $96.00 and gave the company an outperform rating in a report on Monday, April 1st. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $89.29.

Shares of GBT traded down $3.54 during mid-day trading on Friday, hitting $53.98. 3,009,084 shares of the stock were exchanged, compared to its average volume of 726,156. The stock has a market capitalization of $3.24 billion, a price-to-earnings ratio of -15.83 and a beta of 1.79. Global Blood Therapeutics has a 52-week low of $30.15 and a 52-week high of $63.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 14.51 and a quick ratio of 14.51.

Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.94) by $0.07. On average, sell-side analysts expect that Global Blood Therapeutics will post -3.82 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the stock. Truvestments Capital LLC bought a new position in Global Blood Therapeutics in the 1st quarter valued at $33,000. Kore Private Wealth LLC bought a new position in Global Blood Therapeutics in the 1st quarter valued at $53,000. Lindbrook Capital LLC bought a new position in Global Blood Therapeutics in the 4th quarter valued at $55,000. Bank of Montreal Can grew its position in Global Blood Therapeutics by 61.9% in the 4th quarter. Bank of Montreal Can now owns 1,582 shares of the company’s stock valued at $65,000 after acquiring an additional 605 shares during the last quarter. Finally, Strs Ohio bought a new position in Global Blood Therapeutics in the 4th quarter valued at $65,000.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

See Also: Dividend Achievers

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.